Startup profile for Fortuna Health: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Fortuna Health funding, valuation and investors

Consumer-first platform simplifying Medicaid enrollment, navigation, and recertification.

Keep track of Fortuna Health

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A

$18M · 2025

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$22M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series a

Investors in latest funding

Lead: Andreessen Horowitz

Other: Box Group

Sources: latest funding · businesswire.com Last verified: 2026-07-25

Overview

Fortuna Health is a consumer-facing platform that helps people enroll in Medicaid, navigate coverage options, and complete recertification — reducing friction in a process that is often paper-heavy and confusing.

Why Fortuna Health is interesting

Fortuna Health modernizes Medicaid access for underserved consumers; a16z led seed and Series A with BoxGroup in both rounds.

Product & use cases

Consumer-first platform simplifying Medicaid enrollment, navigation, and recertification.

  • Medicaid enrollment for eligible consumers
  • Coverage navigation and plan selection
  • Recertification reminders and assistance

Key facts

  • Series A (2025): $18M led by a16z (/fund/andreessen-horowitz) with BoxGroup (/fund/box-group) participation (BusinessWire)
  • Seed (2023): $4M led by a16z Bio + Health with BoxGroup (BusinessWire)

Funding history (newest first)

Series A

2025 $18M

Source: Read source · businesswire.com

Seed

2023 $4M

Source: Read source · businesswire.com

Investors in our directory

Funds linked from Fortuna Health's profile — open a fund page for stage focus and related deal articles.

andreessen-horowitz box-group

Competitive landscape

Edge: Consumer-facing Medicaid access vs B2B-only payer tools — a16z led both seed and Series A with BoxGroup.

Medicaid enrollment is high-friction for millions of Americans. Fortuna's $18M Series A (2025) after $4M seed (2023) targets the consumer experience gap — a16z Bio + Health thesis.

  • Healthcare.gov incumbent

    Federal marketplace; Fortuna focuses Medicaid specifically.

  • State Medicaid portals incumbent

    Often confusing UX; Fortuna offers guided experience.

  • Health plan broker tools adjacent

    Agent-focused; Fortuna is consumer-direct.

Notable stories

  • Fortuna Health raised back-to-back rounds from a16z and BoxGroup as Medicaid redeterminations surged post-pandemic (BusinessWire).

Industries

healthtech

Market / IPO context

Editorial / static context — not a live quote.

FAQs about Fortuna Health

Practical answers founders, operators, and investors typically search for.

Fortuna Health helps consumers enroll in Medicaid, understand coverage options, and complete recertification through a digital-first platform designed for underserved populations.
Andreessen Horowitz (/fund/andreessen-horowitz) led Fortuna Health's $4M seed (2023) and $18M Series A (2025). BoxGroup (/fund/box-group) participated in both rounds.
Fortuna Health is at Series A based on its 2025 $18M round.
Medicaid enrollment and recertification are high-friction, high-stakes processes for millions of Americans. Fortuna targets the consumer experience gap rather than selling only to payers or providers.
No. Fortuna Health remains a private company.
Consumers eligible for or enrolled in Medicaid seeking enrollment or recertification help.
$22M across seed ($4M) and Series A ($18M).
See company website for current headquarters.
All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.